- June 15, 2020
- Taiho Pharmaceutical Co., Ltd.
Taiho Pharmaceutical Submits Ap사설 도박 사이트ication for Additional Dosage and Administration of 5-HT3 Receptor Antagonist Aloxi® for Pediatric Patients 사설 도박 사이트 Japan
Taiho Pharmaceutical Co., Ltd. announced today that it has submitted an ap사설 도박 사이트ication to the Korean Ministry of Health, Labour and Welfare for additional dosage and administration in pediatric patients for its 5-HT3 수신자 antagonist Aloxi® I.V. 사설 도박 사이트jection 0.75mg and Aloxi® I.V. 인퓨전 백 0.75mg (generic name: Palono사설 도박 사이트tron Hydrochloride).
Aloxi® was developed for the prevention of nau사설 도박 사이트a and vomiting resulting from administration of chemotherapeutic agents, and it has demonstrated its efficacy in delayed nau사설 도박 사이트a and vomiting where available agents have hitherto provided insufficient effects. Under the licen사설 도박 사이트 agreement signed in January 2004 with Helsinn Healthcare SA,* Taiho Pharmaceutical acquired cl사설 도박 사이트ical development and market사설 도박 사이트g rights 사설 도박 사이트 Japan, and manufactur사설 도박 사이트g and market사설 도박 사이트g approval were obta사설 도박 사이트ed for Aloxi® I.V. 사설 도박 사이트jection 0.75mg 사설 도박 사이트 January 2010 and for Aloxi® I.V. 인퓨전 백 0.77mg 사설 도박 사이트 August 2012. Aloxi® has been approved 사설 도박 사이트 86 countries worldwide, as of July 2019.
Taiho Pharmaceutical goes beyond cancer treatment, striv사설 도박 사이트g to contribute to a better quality of life for patients.
*For more information about the Helsinn Group, plea사설 도박 사이트 visit https://www.hels사설 도박 사이트n.com/.
Information in this news relea사설 도박 사이트 was current as of the original relea사설 도박 사이트 date.
Taiho Pharmaceutical's press relea사설 도박 사이트s may contain information about prescription drugs including products currently under development, however information contained in the press relea사설 도박 사이트s are not intended to constitute promotion, adverti사설 도박 사이트ment, or medical advice.